Wednesday, 14 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 4, 2026

Avery Dennison outlines 6% Q1 2026 EPS growth target as high-value category mix accelerates

View original at seekingalpha.com
Avery Dennison outlines 6% Q1 2026 EPS growth target as high-value category mix accelerates Earnings Call Insights: Avery Dennison Corporation (AVY) Q4 2025 MANAGEMENT VIEW * Deon Stander, President, CEO & Director, stated the company delivered adjusted EPS of $9.53 and $707 million of adjusted free cash flow for 2025,…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Does not anticipate an increase in customer acquisition costs and feels confident in the company's paper supply risk management

    80% confidence
  • We're anticipating Intelligent Labels growth rate in 2026 to be above what we delivered in 2025, and expects high-value categories to grow at mid-single-digit plus

    80% confidence
  • Walmart announcement increased pipeline interest for Intelligent Labels

    80% confidence
  • Base categories were down low single digits in Q4, lower than expected, on softer customer volumes

    80% confidence
  • Restructuring benefits are expected to be somewhat balanced across the year

    80% confidence
  • Ongoing investments in digital capabilities, automation, and AI will enable additional operational productivity and fixed cost innovation, strengthen service and quality, shorten innovation cycles and provide more data-driven solutions

    80% confidence
  • Given key economic indicators remain largely consistent with 2025 levels, we are not planning for any macroeconomic tailwinds in the near term

    80% confidence
  • Key economic indicators remain largely consistent with 2025 levels, no macroeconomic tailwinds planned in the near term

    80% confidence
  • Pricing typically follows raw material input cost changes, with productivity actions aimed at offsetting wage inflation

    80% confidence
  • Anticipating Intelligent Labels growth rate in 2026 to be above what was delivered in 2025, with high-value categories expected to grow at mid-single-digit plus

    80% confidence
  • Intelligent Labels delivered high single-digit growth

    80% confidence
  • Base volumes were soft in the quarter, and productivity actions were used to offset wage inflation, with some onetime items and extra calendar days impacting results

    80% confidence
  • Expects restructuring benefits to be somewhat balanced across the year

    80% confidence
  • Management is not happy with the organic growth trajectory over the last couple of years

    80% confidence
  • Given key economic indicators remain largely consistent with 2025 levels, the company is not planning for any macroeconomic tailwinds in the near term

    80% confidence
  • Continue to drive ongoing productivity all the time in terms of ELS savings, looking at reducing scrap, being more efficient in operations

    80% confidence
  • Pricing typically follows raw material input cost changes, with productivity actions aimed at offsetting wage inflation

    80% confidence
  • High-value categories now represent 38% of the Materials Group portfolio

    80% confidence
  • High-value categories helped balance base categories, which were down low single digits in the quarter, lower than expected, on softer customer volumes

    80% confidence
  • Expect restructuring savings of approximately $50 million as company continues to execute productivity playbook, and expect normalization of majority of 2025 temporary savings

    80% confidence
  • Anticipating Intelligent Labels growth rate in 2026 to be above what was delivered in 2025, expects high-value categories to grow at mid-single-digit plus

    80% confidence
  • Ongoing investments in digital capabilities, automation, and AI will enable additional operational productivity and fixed cost innovation

    80% confidence
  • The company expects restructuring savings of approximately $50 million as it continues to execute its productivity playbook, and expects normalization of a majority of 2025 temporary savings, largely related to lower incentive compensation costs

    80% confidence
  • Walmart rollout would ramp in Q4 2026 and accelerate into 2027

    80% confidence
  • Pricing typically follows raw material input cost changes, with productivity actions aimed at offsetting wage inflation

    80% confidence
  • Materials Group saw reported sales increase 5%, with high-value categories now representing 38% of the segment's portfolio, and Intelligent Label delivering high single-digit growth

    80% confidence
  • Walmart rollout would ramp in Q4 2026 and accelerate into 2027

    80% confidence
  • The temporary savings headwind is on an order of magnitude basis probably pretty similar to the size of the restructuring actions, that $50 million

    80% confidence
  • Does not anticipate an increase in customer acquisition costs and feels confident in the company's paper supply risk management

    80% confidence
  • I'm not happy with the way our organic growth trajectory has been over the last couple of years

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Avery Dennison outlines 6% Q1 2026 EPS growth target as high-value category mix accelerates — Source | Via News | ViaNews EU